ClinicalTrials.gg
CompletedNCT02069041Updated Nov 21, 2018Results posted

A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer

A Phase 1 interventional study of Ramucirumab and FOLFOX4 in Carcinoma, Hepatocellular, sponsored by Eli Lilly and Company. Completed at 3 sites in Taiwan. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-11-21.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
20 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Carcinoma, Hepatocellular by Eli Lilly and Company — none open to participants now, none under way, none of them phase 3. Carcinoma, Hepatocellular · Eli Lilly and Company.

Enrollment
11th of 13
8 · median 47
Started
2014
with 2 others
Phase 1
4 of 13
none open now
Registered
6th of 13
by date

Among the 13 studies in Carcinoma, Hepatocellular by Eli Lilly and Company, this one is the 11th largest by enrollment, is one of 3 that started in 2014, is one of 4 in phase 1, and was the 6th registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

None of the 13 studies in Carcinoma, Hepatocellular by Eli Lilly and Company is open now. The open studies under Carcinoma, Hepatocellular, anywhere →

Who these studies take

Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 20 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies in Carcinoma, Hepatocellular by Eli Lilly and Company as a file.
02

Study summary

The main purpose of this study is to determine if the advised dose of ramucirumab is safe to be taken with chemotherapy treatment in participants with advanced liver tumors.

03

Conditions studied

  • Carcinoma, Hepatocellular
04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histological or cytological diagnosis of hepatocellular carcinoma (HCC) or imaging findings consistent with HCC in a participant with liver cirrhosis and alpha-fetoprotein > 200 nanogram per milliliter
  • At least 1 measurable or non-
  • A
  • Barcelona Clinic Liver Cancer (BCLC) stage C or BCLC stage B not amenable to locoregional therapy or to locoregional therapy
  • Performance Status of 0 or 1
  • Have not received previous systemic therapy for advanced HCC
  • Have resolution to Grade ≤1 of all toxic effects of prior locoregional therapy
  • Adequate organ function including: Absolute neutrophil coun t≥1.5×109/liter (L), ≥9 gram/deciliter, and ≥90×109/L; Total level ≤1.5 the (ULN), and alanine transaminase ≤5 ULN, albumin >28 gram/L; Serum creatinine level ≤1.5 ULN; or calculated serum ≥50 milliliter/minute; ≤1.5 and partial thromboplastin time ≤5 seconds above ULN
  • The urinary protein is ≤ 1+. If ≥ 2+ proteinuria, the 24-hour urine protein is \<1000 milligram
  • An estimated of at least 12 weeks

Exclusion criteria

Exclusion Criteria:

  • Received any therapy or non-approved drug within 28 days prior to enrollment
  • Undergone major surgery within 28 days prior to enrollment, or undergone central venous access device placement within 7 days prior to enrollment
  • Undergone hepatic locoregional therapy within 28 days prior to enrollment
  • Undergone radiation to any nonhepatic site within 14 days prior to enrollment
  • Prior liver transplant
  • Fibrolamellar carcinoma or cholangiocellular carcinoma
  • Received any transfusion, blood component preparation, erythropoietin, albumin preparation, or granulocyte-colony stimulating factors within 14 days prior to enrollment
  • Receiving therapeutic anticoagulation with warfarin, low-molecular weight heparin, or similar agents
  • Receiving ongoing therapy with nonsteroidal anti-inflammatory agents or other antiplatelet agents.
  • Known infection or acquired immunodeficiency syndrome-related illness
  • Active or uncontrolled clinically serious infection
  • Uncontrolled thrombotic or hemorrhagic disorder
  • Serious or nonhealing wound, ulcer, or bone fracture within 28 days prior to enrollment
  • History of gastrointestinal perforation or obstruction
  • History of or current hepatic encephalopathy or current ascites
  • Known allergy to monoclonal antibody, fluorouracil, oxaliplatin or their
  • Interstitial pneumonia or interstitial fibrosis of the lung
  • Central nervous system or carcinomatous meningitis
  • Known history of dihydropyrimidine dehydrogenase deficiency
  • Symptomatic congestive heart failure, unstable angina pectoris, or symptomatic or poorly controlled cardiac arrhythmia
  • Experienced any arterial thromboembolic event
  • Uncontrolled arterial hypertension
  • Grade 3-4 venous thromboembolic events occurring within 3 months prior to enrollment
  • Experienced any grade 3-4 gastrointestinal bleeding or any variceal bleeding episode in the 3 months prior to enrollment requiring transfusion, endoscopic or operative intervention
  • Esophageal or gastric varices that require immediate intervention or represent a high bleeding risk
  • Pre-existing grade ≥ 2 motor or sensory neuropathy
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Ramucirumab + FOLFOX4

    8 milligram/kilogram (mg/kg) ramucirumab given intravenously (IV) on Day 1 followed by FOLFOX4 (folinic acid + fluorouracil + oxaliplatin chemotherapy regimen) given IV on Day 1 of 2 week cycles: FOLFOX4 every 2 weeks: 85 milligram per square meter (mg/m²) oxaliplatin IV on Day 1 200 mg/m² folinic acid(FA) IV on days 1 and 2 400 mg/m² 5-FU bolus on days 1 and 2 600 mg/m2 5-FU 22-h continuous infusion on Days 1 and 2 Participants may continue to receive treatment until discontinuation criteria are met.

    Biological: Ramucirumab · Drug: FOLFOX4

Interventions

  • BiologicalRamucirumab

    Administered IV.

    Also known as: IMC-1121B, LY3009806

  • DrugFOLFOX4

    Administered IV.

    Also known as: FOLFOX4 (leucovorin + fluorouracil + oxaliplatin)

06

What researchers measure

Primary outcomes

  1. Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

    A summary of other non-serious Adverse Events (AEs), and all Serious Adverse Events (SAE's), regardless of causality, is located in the Reported Adverse Events section.

    Time frame: Baseline through study completion (Up To 8 Months)

Secondary outcomes

  1. Pharmacokinetics (PK): Maximum Concentration (Cmax) of Ramucirumab

    Maximum Concentration (Cmax)

    Time frame: Cycle 1 and Cycle 3: 0,1.0,1.5,2.0,3.0,5.0,24.0,48.0,168.0,336.0 hours

  2. PK:Area Under the Concentration-Time Curve (AUC[0-∞]) of Ramucirumab

    Area under the concentration-time curve.

    Time frame: Cycle 1 and Cycle 3: 0,1.0,1.5,2.0,3.0,5.0,24.0,48.0,168.0,336.0 hours

  3. Number of Participants With Anti-Ramucirumab Antibodies

    Time frame: Baseline through 6.1 Months

  4. Percentage of Participants With Best Response of Complete Response (CR) or Partial Response (PR) (Overall Response Rate [ORR])

    Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST, version\[v\] 1.1) criteria.CR was defined as the disappearance of all target and non-target lesions and all target and non-target lymph nodes were non-pathological or normal in size \[\<10 millimeter (mm) short axis\]. PR is at least a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters. Progressive Disease(PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (including the baseline sum if that is the smallest).In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression. Percentage of participants with CR or PR= (number of participants whose best overall response was CR or PR)/(number of participants treated)\*100.

    Time frame: Response to Disease Progression or Death (Up To 7 Months)

07

Results

Posted Nov 21, 2018

Participant flow

Participant flow — Overall Study
MilestoneRamucirumab + FOLFOX4
Started8
Received at least one dose of study drug8
Completed8
Not completed0

Outcome measures

PrimaryNumber of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

A summary of other non-serious Adverse Events (AEs), and all Serious Adverse Events (SAE's), regardless of causality, is located in the Reported Adverse Events section.

Time frame:
Baseline through study completion (Up To 8 Months)
Reported as:
Count of participants · Participants
Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
ParticipantsRamucirumab + FOLFOX4
Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration4
SecondaryPharmacokinetics (PK): Maximum Concentration (Cmax) of Ramucirumab

Maximum Concentration (Cmax)

Time frame:
Cycle 1 and Cycle 3: 0,1.0,1.5,2.0,3.0,5.0,24.0,48.0,168.0,336.0 hours
Reported as:
Geometric mean · ug/mL(microgram / milliliter)
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Ramucirumab
ug/mL(microgram / milliliter)Ramucirumab + FOLFOX4
Cycle 1155 ± 25
Cycle 3190 ± 29
SecondaryPK:Area Under the Concentration-Time Curve (AUC[0-∞]) of Ramucirumab

Area under the concentration-time curve.

Time frame:
Cycle 1 and Cycle 3: 0,1.0,1.5,2.0,3.0,5.0,24.0,48.0,168.0,336.0 hours
Reported as:
Geometric mean · microgram*day / milliliter)(ug*day/mL)
PK:Area Under the Concentration-Time Curve (AUC[0-∞]) of Ramucirumab
microgram*day / milliliter)(ug*day/mL)Ramucirumab + FOLFOX4
Cycle 1940 ± 24
Cycle 31190 ± 25
SecondaryNumber of Participants With Anti-Ramucirumab Antibodies
Time frame:
Baseline through 6.1 Months
Reported as:
Count of participants · Participants
Number of Participants With Anti-Ramucirumab Antibodies
ParticipantsRamucirumab + FOLFOX4
Number of Participants With Anti-Ramucirumab Antibodies0
SecondaryPercentage of Participants With Best Response of Complete Response (CR) or Partial Response (PR) (Overall Response Rate [ORR])

Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST, version\[v\] 1.1) criteria.CR was defined as the disappearance of all target and non-target lesions and all target and non-target lymph nodes were non-pathological or normal in size \[\<10 millimeter (mm) short axis\]. PR is at least a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters. Progressive Disease(PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (including the baseline sum if that is the smallest).In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression. Percentage of participants with CR or PR= (number of participants whose best overall response was CR or PR)/(number of participants treated)\*100.

Time frame:
Response to Disease Progression or Death (Up To 7 Months)
Reported as:
Number · percentage of Participants
Percentage of Participants With Best Response of Complete Response (CR) or Partial Response (PR) (Overall Response Rate [ORR])
percentage of ParticipantsRamucirumab + FOLFOX4
Percentage of Participants With Best Response of Complete Response (CR) or Partial Response (PR) (Overall Response Rate [ORR])25

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ramucirumab + FOLFOX4—5/8 (62.5%)8/8 (100%)
Most frequent serious events
Most frequent serious events
EventRamucirumab + FOLFOX4
PyrexiaGeneral disorders3/8
AscitesGastrointestinal disorders2/8
Neutrophil count decreasedInvestigations2/8
Hepatic haemorrhageHepatobiliary disorders1/8
BacteraemiaInfections and infestations1/8
Peritonitis bacterialInfections and infestations1/8
Blood bilirubin increasedInvestigations1/8
Lung infiltrationRespiratory, thoracic and mediastinal disorders1/8
Most frequent other events
Showing 10 of 66
Most frequent other events
EventRamucirumab + FOLFOX4
Abdominal painGastrointestinal disorders6/8
DiarrhoeaGastrointestinal disorders5/8
Neutrophil count decreasedInvestigations5/8
Decreased appetiteMetabolism and nutrition disorders5/8
NauseaGastrointestinal disorders4/8
FatigueGeneral disorders4/8
Platelet count decreasedInvestigations4/8
HypoalbuminaemiaMetabolism and nutrition disorders4/8
AnaemiaBlood and lymphatic system disorders3/8
Abdominal pain upperGastrointestinal disorders3/8

Baseline characteristics

All participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Ramucirumab + FOLFOX4
Mean55.56 ± 11.06
Sex: Female, Male
Sex: Female, Male(Participants)Ramucirumab + FOLFOX4
Female2
Male6
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ramucirumab + FOLFOX4
Hispanic or Latino0
Not Hispanic or Latino8
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ramucirumab + FOLFOX4
American Indian or Alaska Native0
Asian8
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Ramucirumab + FOLFOX4
Taiwan8
Basis of Initial Pathological Diagnosis
Basis of Initial Pathological Diagnosis(Participants)Ramucirumab + FOLFOX4
Histopathological3
Cytological1
Biochemical Assay and Imaging2
Disease Stage
Disease Stage(Participants)Ramucirumab + FOLFOX4
Stage I0
Stage II1
Stage III4
Stage IV1
Unknown0
Duration of Disease (months)
Duration of Disease (months)(months)Ramucirumab + FOLFOX4
Median0.345 (0.23 to 0.66)

3 further baseline measures are reported on the registry.

08

Study locations

3 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tainan, 70403, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Taipei, 10048, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Taoyuan City, 33305, Taiwan
09

References and documents

Publications

  • Lin CC, Yang TS, Yen CJ, Cheng R, Liu J, Hsu C. Safety and Preliminary Efficacy of Ramucirumab in Combination with FOLFOX4 in Patients with Advanced Hepatocellular Carcinoma: A Nonrandomized, Open-Label, Phase Ib Study. Oncologist. 2020 Dec;25(12):e1921-e1929. doi: 10.1002/onco.13550. Epub 2020 Oct 31. PubMed 33017497 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2014, a primary completion of Sep 2016 and a completion of Sep 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2018, 2 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2014
First posted
Feb 21, 2014
Start
Apr 2014
Primary completionActual
Sep 2016
CompletionActual
Sep 2016
Results first posted
Nov 21, 2018
Last update
Nov 21, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02069041
Responsible party
Sponsor
First posted
Feb 21, 2014
Start date
Apr 2014
Primary completion
Sep 2016
Completion
Sep 2016
Results posted
Nov 21, 2018
Last update
Nov 21, 2018

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ramucirumab

Start the discussion